AMCP 2022
High Out-of-Pocket Costs Mean Lower Adherence for Cancer, Autoimmune Medications
CHICAGO—Patients facing high out-of-pocket costs for medications for cancer and autoimmune conditions are ...
JUNE 28, 2022
Drug Launches Persist Amid Pandemic
Healthcare offices readjusted to a new normal in 2021 during the peak of the COVID-19 pandemic, but new drug ...
JUNE 22, 2022
4 Value-Based Contracting Strategies
Value-based contracts provide an opportunity for manufacturers to evaluate outcomes not studied in clinical trials, ...
JUNE 6, 2022
Machine Learning Helps Predict Sepsis Readmissions
CHICAGO—A machine learning model for sepsis may better predict total and 30-day hospital readmissions for ...
JUNE 2, 2022
Biosimilars for Oncology Gaining Ground
CHICAGO—Biosimilars for oncology are gaining ground, with more payors implementing strategies to cover them ...
APRIL 1, 2022
Value-Based Contracting Likely to Continue Evolving
CHICAGO—Value-based contracts can provide opportunities for manufacturers to evaluate clinically appropriate ...
APRIL 1, 2022
Cooking Up a Forecasting Model to Budget for a New Specialty Drug
CHICAGO—In 2019, specialty medications accounted for 65% of all new drug approvals, rising to 74% by 2021. ...
MARCH 31, 2022
Digital Therapeutics Hold Promise for Behavioral Health
CHICAGO—Digital therapeutics could serve as effective complementary therapies for behavioral health ...
MARCH 31, 2022
